6.51
+0.04(+0.62%)
Currency In USD
| Previous Close | 6.47 |
| Open | 6.3 |
| Day High | 6.56 |
| Day Low | 6.3 |
| 52-Week High | 36.2 |
| 52-Week Low | 5.9 |
| Volume | 1.19M |
| Average Volume | 2.94M |
| Market Cap | 475.17M |
| PE | -9.86 |
| EPS | -0.66 |
| Moving Average 50 Days | 7.6 |
| Moving Average 200 Days | 18.72 |
| Change | 0.04 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $405.61 as of May 24, 2025 at a share price of $6.51. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $146.56 as of May 24, 2025 at a share price of $6.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire Inc.
Apr 28, 2025 11:00 AM GMT
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review fir
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 10:45 AM GMT
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evalu
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 2:44 PM GMT
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3